logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q4 2018
PROTEON THERAPEUTICS INC
Top line data from 2nd phase III trial of Vonapanitase (PATENCY 2)
chronic kidney disease (CKD)
Q4 2018
Clearside Biomedical, Inc.
Preliminary data from first phase III trial of CLS-TA (SAPPHIRE)
Retinal Vein Occlusion
Q4 2018
Zosano Pharma Corporation
6-month safety data of long-term study of M207
Migraine
Q4 2018
Biohaven Pharmaceutical Holding Co Ltd.
Topline results 3rd phase III efficacy study of Rimegepant
Migraine
Early Q4 2018
GTX Inc.
Top-line results from phase II clinical trial of Enobosarm (ASTRID)
stress urinary incontinence in postmenopausal women
Q4 2018
Aeglea BioTherapeutics, Inc.
Topline results from Phase 1 cohort expansions with Pegzilarginase (AEB1102)
Uveal and Cutaneous Melanoma
Q4 2018
Ocular Therapeutix Inc.
Topline results from phase III trial of OTX-TP
Glaucoma
Q4 2018
OncoMed Pharmaceuticals Inc
Data from phase Ia single agent study of OMP-313M32
Solid tumors
Q4 2018
ObsEva SA
Results of live birth rates and 28-day neonatal safety from phase III clinical trial of Nolasiban(IMPLANT2) 
IVF
Q4 2018
Calithera Biosciences Inc.
Update on TNBC development program from phase II trial of CX-839-007 with paclitaxel
Triple negative breast cancer
Q4 2018
Sophiris Bio Inc.
Final biopsy data from phase II study receiving second administration of Topsalysin
Prostate cancer in men
Q4 2018
Conatus Pharmaceuticals Inc
Top-line results from phase IIb trial of Emricasan (ENCORE-PH)
Liver cirrhosis caused by nonalcoholic steatohepatitis (NASH), and severe portal hypertension
Q4 2018
Applied Genetic Technologies Corp.
Topline data from clinical phase I/II study of AAV-based gene therapy candidate
x-linked retinoschisis (XLRS)
Q4 2018
Aptevo Therapeutics Inc
Preliminary data from phase II trial of Otlertuzumab
Peripheral T-cell lymphoma
Q4 2018
Aptevo Therapeutics Inc
Submission of IND for APVO210
Autoimmune/Inflammatory Diseases
Q4 2018
Aptevo Therapeutics Inc
Preliminary data from Phase 1 dose escalation study of APVO414
Metastatic castration resistant prostate cancer
Q4 2018
Heat Biologics Inc.
Interim phase II data readout of HS-110
Non Small Cell Lung Cancer (NSCLC)
Q4 2018
Heat Biologics Inc.
Filing of IND for first ComPACT trial of HS-130
Non Small Cell Lung Cancer (NSCLC)
Q4 2018
Xencor Inc
Top line data from phase II trial of XmAb5871
Systemic Lupus Erythematosus (SLE)
Late Q4 2018
Asterias Biotherapeutics, Inc.
12-month update from entire phase 1/2a study of AST-OPC1 (SCiStar), including Cohort 5
Acute spinal cord injury
Q4 2018
BeyondSpring Inc.
Phase 3 interim data for Study 103 evaluating Plinabulin + docetaxel
Non-small cell lung cancer (NSCLC)
Q4 2018
BeyondSpring Inc.
Data from Phase 3 interim analysis for Study 105 evaluating Plinabulin + docetaxel
Chemotherapy-induced neutropenia (CIN)
Q4 2018
Sierra Oncology, Inc.
Preliminary data from monotherapy phase 1/2 trial of SRA737
Solid Tumors or Non-Hodgkin's Lymphoma
Q4 2018
Sierra Oncology, Inc.
Update from SRA737 phase 1/2 Low-Dose Gemcitabine combination trial into the cohort expansion phase II portion
Advanced Solid Tumors
Q4 2018
Mirati Therapeutics, Inc.
IND filing of MRTX849
Non-small cell lung cancer